Skip to content
Menu

Zymeworks Inc. ZYME

Full chart Compare
Set alert

Price alert · ZYME

All alert types
26.14 USD -0.72 (-2.68%)

Regular-session close

26.14 0.00 0.00%

After hours · Nov 20, 4:00 PM ET

26.09 Day range 27.56
21.52 52-week range 31.97
YTD
-0.72%
1 year
+9.74%

5D -1.31 (-4.77%)

252627MonTueWedThuFri26.14
Market cap
1.81B
Revenue (ttm)
265.97M
Profit margin
16.28%
EPS (ttm)
0.53
Shares out
68.70M
P/E ratio
49.32
Forward P/E
54.95
YTD return
-0.72%
1-year return
+9.74%
50-day average
27.21
Volume
738.81K
Avg volume
1.09M
Open
26.30
Previous close
26.86
Day's range
26.09 – 27.56
52-week range
21.52 – 31.97
Beta
1.30
Analysts
Strong Buy
Price target
43.29 (+65.6%)
Earnings date
Mar 1, 2027

Key statistics

200-day average
25.59
Enterprise value
1.81B
Price / sales
6.80
Price / book
7.21
Revenue growth
828.70%
Free cash flow
-195.69M
Total cash
100.46M
Total debt
53.13M
Return on equity
14.98%
Short % of float
12.89%

Fundamental scorecard

8 of 25 checks passed on ZYME’s reported financials

ValueGrowthProfitabilityHealthDividend

8of 25 checks passed

  • Value 1 of 5
  • Growth 3 of 5
  • Profitability 2 of 5
  • Financial health 2 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ZYME Revenue — quarterly 256.46M
ZYME Net income — quarterly 173.70M
ZYME EPS — quarterly 2.43

Earnings

ZYME recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 1, 2027Dec 30, 20260.1257———
Nov 9, 2026Sep 30, 20262.272.28+0.01+0.44%
Aug 6, 2026Jun 30, 2026-0.57467-0.62-0.05-7.89%
May 7, 2026Mar 31, 2026-0.10-0.59-0.49-490.00%
Mar 2, 2026Dec 31, 2025-0.35-0.55-0.20-57.14%
Nov 6, 2025Sep 30, 2025-0.30-0.26+0.04+13.33%

Upgrades / downgrades

ZYME analyst upgrades and downgrades
DateFirmActionFromTo
Nov 11, 2026CitigroupmainBuyBuy
Nov 10, 2026TD CowenmainBuyBuy
Nov 10, 2026Truist SecuritiesmainBuyBuy
Nov 10, 2026HC Wainwright & Co.mainBuyBuy
Oct 28, 2026Truist SecuritiesmainBuyBuy
Oct 7, 2026Truist SecuritiesmainBuyBuy

About Zymeworks Inc.

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on ZYME — it syncs with the Stock Master app.

Insider holders

ZYME insider holders
InsiderRelationLatest transactionDateShares held
CIONGOLI GREGORY AUSTINDirectorStock Award(Grant)Aug 11, 2025493,500
ECOR1 CAPITAL, L.L.C.Beneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityJun 25, 20250
GALBRAITH KENNETH HARRYChief Executive OfficerSaleJan 11, 2026226,842
HOLLYWOOD MARKChief Operating OfficerStock Award(Grant)Jul 5, 2026133,852
MOORE PAUL ANDREWOfficerSaleNov 12, 202633,756
PATTERSON LEONE D. CPAChief Financial OfficerStock Award(Grant)Jan 5, 2026459

Institution ownership

ZYME institution ownership
Holder% heldSharesValueReported
EcoR1 Capital, LLC36.46%22,970,388600.45MSep 29, 2026
Rubric Capital Management LP11.11%7,000,000182.98MSep 29, 2026
Blackrock Inc.6.69%4,212,745110.12MSep 29, 2026
Perceptive Advisors Llc5.63%3,545,50192.68MSep 29, 2026
BVF Inc.5.50%3,464,14290.55MSep 29, 2026
Morgan Stanley5.14%3,236,91584.61MSep 29, 2026

Fund ownership

ZYME fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.39%1,508,61339.44MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF1.88%1,185,92831.00MSep 29, 2026
IVY FUNDS-Nomura Small Cap Growth Fund0.95%600,84615.71MJun 29, 2026
iShares Trust-iShares Biotechnology ETF0.85%538,11014.07MSep 29, 2026
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund0.82%514,48413.45MAug 30, 2026
iShares Trust-iShares Russell 2000 Growth ETF0.68%425,94911.13MSep 29, 2026